Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered answering member label previous answer version answering member constituency answering member printed answering member label
tabling member	label

Search

1192284

registered interest
date	01/05/2020
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential merits of using camostat mesylate in the treatment of patients with covid-19.
tabling member constituency	Glasgow North
tabling member printed	Patrick Grady
uin	42092
answer	answer is ministerial correction date of answer 15/05/2020 answer text <p>There are currently no approved treatments for COVID-19 and full evaluation of the merits of any potential treatments can only be made once clinical trials involving COVID-19 patients have been completed. The United Kingdom Government is considering a wide range of potential treatments in the current UK clinical trials. Drugs representing a range of relevant modes of action including - but not limited to - serine protease inhibitors, such as camostat, are being reviewed and prioritised by a panel of experts so that the most promising are put into clinical trials first.</p> answering member constituency Bury St Edmunds answering member printed Jo Churchill question first answered 15/05/2020 11:25:11 answering member 4380 label Biography information for Jo Churchill previous answer version 19579 answering member constituency Bury St Edmunds answering member printed Jo Churchill answering member 4380 label Biography information for Jo Churchill
tabling member	4432 label Biography information for Patrick Grady

1192285

registered interest
date	01/05/2020
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential merits of using therapeutic plasma in the treatment of patients with covid-19.
tabling member constituency	Glasgow North
tabling member printed	Patrick Grady
uin	42093
answer	answer is ministerial correction date of answer 11/05/2020 answer text <p>On 25 April, the Department announced that the clinical trial REMAP-CAP was given approval to determine as part of a trial, if plasma donated by patients who have recovered from COVID-19 can help those with the virus. NHS Blood and Transplant has started to collect convalescent plasma to supply to REMAP-CAP and the first transfusion took place last week.</p><p>In parallel with the trial, NHS Blood and Transplant is scaling up a national programme for collecting plasma so the treatment can be widely rolled out if it is shown to be effective. The collection of plasma will be ramped up by mid-May to deliver up to 10,000 units of plasma to the National Health Service every week, enough to treat 5,000 COVID-19 patients per week.</p><p>Convalescent plasma has been used as an effective treatment for emerging infections in the past, and this step forward underpins the Department’s scientific approach to fighting this virus.</p> answering member constituency Faversham and Mid Kent answering member printed Helen Whately question first answered 11/05/2020 11:36:35 answering member 4527 label Biography information for Helen Whately previous answer version 19580 answering member constituency Bury St Edmunds answering member printed Jo Churchill answering member 4380 label Biography information for Jo Churchill
tabling member	4432 label Biography information for Patrick Grady

1192287

registered interest
date	01/05/2020
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what funding his Department is providing for research into the potential merits of using therapeutic plasma in the treatment of patients with covid-19.
tabling member constituency	Glasgow North
tabling member printed	Patrick Grady
uin	42094
answer	answer is ministerial correction date of answer 11/05/2020 answer text <p>The Department invests £1 billion per year in health research through the National Institute for Health Research (NIHR). The NIHR is prioritising clinical research activity on COVID-19 through its national prioritisation process for Urgent Public Health research. The REMAP-CAP trial is one of several studies that have been nationally prioritised. This is a platform clinical trial testing the effectiveness of multiple treatments on COVID-19 patients in intensive care. The NIHR is supporting prioritised studies such as REMAP-CAP to expedite their local set-up, management and delivery through the NIHR Clinical Research Network. As announced on 25 April, the Department is working in collaboration with NHS Blood and Transplant and the other United Kingdom blood services, Public Health England and NHS Digital to enable the testing of convalescent plasma through this trial. Details of funding for this will be made publicly available shortly.</p> answering member constituency Faversham and Mid Kent answering member printed Helen Whately question first answered 11/05/2020 11:24:23 answering member 4527 label Biography information for Helen Whately previous answer version 19581 answering member constituency Faversham and Mid Kent answering member printed Helen Whately answering member 4527 label Biography information for Helen Whately
tabling member	4432 label Biography information for Patrick Grady